Investigational drug · Phase 3
VYD222
Also called: pemivibart
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for COVID-19, SARS-CoV-2.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "VYD222"
First trial start
2023
Sep 8, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VYD222", any sponsor or status.
Conditions studied
As listed on its trial records.
- COVID-19
- SARS-CoV-2
Approved drugs for the same conditions: COVID-19 · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "VYD222" as an intervention, largest first.
- A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2Pivotal-lookingCompleted
Invivyd, Inc.Industry
NCT06039449 · 790 participants · Start Sep 8, 2023 · Primary completion Nov 19, 2024
Drug: VYD222 (pemivibart); Normal saline · For: COVID-19; SARS-CoV-2
Sites: Fullerton, California; Long Beach, California; Rolling Hills Estates, California · 18 sites in all
Invivyd, Inc.Industry
NCT05791318 · 30 participants · Start Mar 28, 2023 · Primary completion May 8, 2024
Drug: VYD222 · For: COVID-19
Sites: Joondalup, Australia
- Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other TreatmentsNo longer available
Invivyd, Inc.Industry
NCT06004128
Drug: VYD222 · For: COVID-19
Newest research
PubMed records naming it or its code names, newest first.
- Organoid-based evaluation of SA55 and Pemivibart against evolving SARS-CoV-2 variants.
Wan Z, Zhou Y, Jian F, et al. · Emerg Microbes Infect 2026
- Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19.
Narayan K, Tosh K, Holmes A, et al. · J Infect Dis 2026
- Cross-neutralization of SARS-CoV-2 BA.3.2.2 lineage by JN.1 mRNA vaccine-induced immunity.
Miyakawa K, Sano K, Seki Y, et al. · Int J Infect Dis 2026
- Immunobridging Analysis of Pemivibart for the Treatment of COVID-19: A Therapeutic Gap for the Immune-Compromised Population Remains.
Holmes A, Narayan K, Yalcin I, et al. · Open Forum Infect Dis 2026
- CROI 2026: Acute and Postacute COVID-19.
Antar AAR · Top Antivir Med 2026
- A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19.
Yalcin I, Hu L, West B, et al. · Infect Dis Ther 2026
Also in development for COVID-19
- Investigational Influenza VaccinePhase 34 trials
BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)
- VYD2311Phase 32 trials
Invivyd, Inc. · Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine
- DAS181Phase 31 trial
Ansun Biopharma, Inc. · Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised
- SCTA01Phase 31 trial
Sinocelltech Ltd. · COVID-19, SARS-CoV-2
- VYD2311-MDPhase 31 trial
Invivyd, Inc. · COVID-19
- VYD2311-SDPhase 31 trial
Invivyd, Inc. · COVID-19
- CVXGACVXGA50, PIV5-SARS CoV-2Phase 22 trials
CyanVac LLC · COVID-19
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.